These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12095377)

  • 1. Loss of HIV-1-specific immunity during treatment interruption in 2 chronically infected patients.
    Blankson JN; Gallant JE; Quinn TC; Bartlett JG; Siliciano RF
    JAMA; 2002 Jul; 288(2):162-4. PubMed ID: 12095377
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV-specific CD4+ T cells and viremia: who's in control?
    Jansen CA; van Baarle D; Miedema F
    Trends Immunol; 2006 Mar; 27(3):119-24. PubMed ID: 16458605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients.
    Keh CE; Shen JM; Hahn B; Hallahan CW; Rehm CA; Thaker V; Wynne SM; Davey RT; Lane HC; Sereti I
    AIDS; 2006 Feb; 20(3):361-9. PubMed ID: 16439869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV neutralizing antibody titer during structured treatment interruption of highly active antiretroviral therapy.
    Nicastri E; Dori L; Buonomini AR; Tommasi C; De Nardo P; Bellagamba R; Corpolongo A; Montano M; Sordillo P; Volpi A; Sarmati L; Andreoni M
    AIDS; 2012 Jul; 26(11):1451-2. PubMed ID: 22767346
    [No Abstract]   [Full Text] [Related]  

  • 5. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART.
    Jones LE; Perelson AS
    Bull Math Biol; 2005 Nov; 67(6):1227-51. PubMed ID: 16023709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 and immune control: can we change the course of HIV-1?
    Kovacs A; Connors M
    Lancet; 2004 Mar; 363(9412):833-4. PubMed ID: 15031022
    [No Abstract]   [Full Text] [Related]  

  • 7. Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study.
    Sullivan SG; Hirsch HH; Franceschi S; Steffen I; Amari EB; Mueller NJ; Magouras I; Biggar RJ; Rickenbach M; Clifford GM;
    AIDS; 2010 Sep; 24(14):2245-52. PubMed ID: 20543658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune activation in chronic HIV infection.
    Ostrowski SR
    Dan Med Bull; 2010 Mar; 57(3):B4122. PubMed ID: 20298670
    [No Abstract]   [Full Text] [Related]  

  • 9. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
    Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution.
    Blankson JN; Gallant JE; Siliciano RF
    J Infect Dis; 2001 Feb; 183(4):657-61. PubMed ID: 11170994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400 x 10(6) cells/l.
    Thiébaut R; Pellegrin I; Chêne G; Viallard JF; Fleury H; Moreau JF; Pellegrin JL; Blanco P
    AIDS; 2005 Jan; 19(1):53-61. PubMed ID: 15627033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells.
    Kostense S; Otto SA; Knol GJ; Manting EH; Nanlohy NM; Jansen C; Lange JM; van Oers MH; Miedema F; van Baarle D
    Eur J Immunol; 2002 Apr; 32(4):1080-9. PubMed ID: 11920575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-specific immunity during structured antiviral drug treatment interruption.
    Moss RB; Brandt C; Giermakowska WK; Savary JR; Theofan G; Zanetti M; Carlo DJ; Wallace MR
    Vaccine; 2003 Mar; 21(11-12):1066-71. PubMed ID: 12559781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordant movement of CD4-positive T-cell count in HIV-1 infected patients with HAART failure.
    Okano A; Matsuda M; Chiba T; Moriya K; Yamada K; Sugiura W
    Jpn J Infect Dis; 2002 Apr; 55(2):62-5. PubMed ID: 12082315
    [No Abstract]   [Full Text] [Related]  

  • 15. A look at HIV immune research. Interview by Alan Huff.
    Landay A
    Res Initiat Treat Action; 2000 Sep; 6(3):30-3. PubMed ID: 11708165
    [No Abstract]   [Full Text] [Related]  

  • 16. Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy.
    Siddique MA; Hartman KE; Dragileva E; Dondero M; Gebretsadik T; Shintani A; Peiperl L; Valentine F; Kalams SA
    J Infect Dis; 2006 Sep; 194(5):661-5. PubMed ID: 16897665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased HIV-specific CD4 T cell proliferation in long-term HIV-infected individuals on antiretroviral therapy.
    Ghanekar SA; Stranford SA; Ong JC; Walker JM; Maino VC; Levy JA
    AIDS; 2001 Sep; 15(14):1885-7. PubMed ID: 11579254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation.
    McNeil AC; Shupert WL; Iyasere CA; Hallahan CW; Mican JA; Davey RT; Connors M
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13878-83. PubMed ID: 11717444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load.
    Gonzalez-Serna A; Glas AC; Brumme CJ; Poon AF; Nohpal De La Rosa A; Mudrikova T; Dias Lima V; Wensing AM; Harrigan R
    J Antimicrob Chemother; 2017 Feb; 72(2):496-503. PubMed ID: 27999069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B cell responses to HIV antigen are a potent correlate of viremia in HIV-1 infection and improve with PD-1 blockade.
    Nicholas KJ; Zern EK; Barnett L; Smith RM; Lorey SL; Copeland CA; Sadagopal S; Kalams SA
    PLoS One; 2013; 8(12):e84185. PubMed ID: 24358343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.